NCT07310784 2026-03-03
A Phase II Trial of LM103 in Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2 Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
University College, London
Swiss Cancer Institute
University of Miami
Institut Bergonié
Linnaeus Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
Sarcoma Oncology Research Center, LLC
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia